**Supplementary File**

Description: Supplementary table

**Title:** Acceptability of Manufacturer-Proposed Utility Values for NICE Cancer Medicine Appraisals: Analysis of Manufacturers’ Information Sources

**Journal:** International Journal of Technology Assessment in Health Care

**Supplementary Table 1. Summary of 136 single technology appraisals in cancer medicines investigated.**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **TA**  **No.** | **Cancer type** | **Measurement of HRQOL used in the main trials** | | | | **Information sources of manufacturer-proposed utility values** | | **Decision by the TAC** | |
| **EQ-5D** | **EORTC QLQ** | **FACT** | **Others** | **Pre-progression** | **Post-progression** | **Pre-progression** | **Post-progression** |
| 214 | Breast cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 215 | Renal cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 216 | Blood and BM cancers | No | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 226 | Blood and BM cancers | No | Yes | Yes | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 239 | Breast cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 258 | Lung cancer | No | No | No | Yes | Literature/TAG | Literature/TAG | Not accepted | Accepted |
| 259 | Prostate cancer | No | Yes | No | Yes | Mapping | Literature/TAG | Not accepted | Not accepted |
| 263 | Breast cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 268 | Skin cancer | No | No | Yes | Yes | Mapping | Mapping | Accepted | Accepted |
| 269 | Skin cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 272 | Bladder cancer | No | No | Yes | No | Mapping | Literature/TAG | Accepted | Not accepted |
| 284 | Ovarian cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 285 | Ovarian cancer | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 306 | Blood and BM cancers | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 307 | Colorectal cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Not accepted |
| 310 | Lung cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 316 | Prostate cancer | Yes | Yes | No | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 319 | Skin cancer | No | Yes | No | No | Mapping | Mapping | Accepted | Accepted |
| 321 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 333 | Renal cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 343 | Blood and BM cancers | No | No | Yes | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 347 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 357 | Skin cancer | Yes | Yes | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 359 | Blood and BM cancers | Yes | Yes | No | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 366 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 370 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 377 | Prostate cancer | Yes | Yes | No | No | EQ-5D | Literature/TAG | Not accepted | Not accepted |
| 378 | Esophageal cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Accepted |
| 380 | Blood and BM cancers | No | No | Yes | No | Mapping | Mapping | Accepted | Accepted |
| 384 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 391 | Prostate cancer | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 395 | Lung cancer | No | No | Yes | No | Mapping | Literature/TAG | Not accepted | Accepted |
| 396 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 399 | Blood and BM cancers | No | No | Yes | No | Mapping | Mapping | Accepted | Accepted |
| 400 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 403 | Lung cancer | Yes | No | No | Yes | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 405 | Colorectal cancer | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 406 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 408 | Blood and BM cancers | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 410 | Skin cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 411 | Lung cancer | Yes | No | No | Yes | EQ-5D | Literature/TAG | Accepted | Accepted |
| 414 | Skin cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 417 | Renal cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 424 | Breast cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 427 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 428 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 429 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 432 | Renal cancer | No | Yes | Yes | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 440 | Pancreatic cancer | No | No | Yes | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 450 | Bladder cancer | No | No | Yes | No | Mapping | Mapping | Accepted | Accepted |
| 462 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 463 | Renal cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 478 | Blood and BM cancers | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 484 | Lung cancer | Yes | No | No | Yes | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 487 | Blood and BM cancers | Yes | No | Yes | Yes | EQ-5D | Literature/TAG | Not accepted | Accepted |
| 488 | Metastases | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 489 | Skin cancer | No | No | No | Yes | Mapping | Mapping | Not accepted | Not accepted |
| 490 | Head and neck cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 492 | Bladder cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Not accepted |
| 495 | Breast cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Accepted |
| 496 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 498 | Renal cancer | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 500 | Lung cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 502 | Bladder cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 503 | Breast cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 505 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 509 | Breast cancer | No | Yes | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 510 | Bladder cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 512 | Renal cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Accepted |
| 513 | Bladder cancer | Yes | Yes | No | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 515 | Breast cancer | No | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 516 | Thyroid cancer | No | Yes | No | Yes | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 517 | Metastases | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Accepted |
| 519 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 520 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 522 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 523 | Blood and BM cancers | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 525 | Bladder cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 528 | Ovarian cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 529 | Bladder cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 530 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 536 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 538 | Head and neck cancers | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 540 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 541 | Bladder cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Not accepted | Not accepted |
| 542 | Renal cancer | No | No | No | No | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 544 | Skin cancer | Yes | No | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 546 | Prostate cancer | Yes | No | No | Yes | EQ-5D | EQ-5D | Accepted | Accepted |
| 551 | Liver cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 553 | Skin cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 554 | Blood and BM cancers | Yes | No | No | Yes | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 557 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 558 | Metastases | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 559 | Blood and BM cancers | Yes | No | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 561 | Blood and BM cancers | No | No | Yes | Yes | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 562 | Skin cancer | Yes | Yes | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 563 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 567 | Blood and BM cancers | No | Yes | No | Yes | Mapping | Mapping | Not accepted | Not accepted |
| 569 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 571 | Lung cancer | No | No | Yes | No | Mapping | Literature/TAG | Accepted | Accepted |
| 573 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 577 | Blood and BM cancers | Yes | No | No | Yes | EQ-5D | EQ-5D | Not accepted | Accepted |
| 578 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 579 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 580 | Prostate cancer | Yes | Yes | Yes | Yes | EQ-5D | EQ-5D | Accepted | Accepted |
| 581 | Renal cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 584 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 587 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 589 | Blood and BM cancers | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Not accepted |
| 592 | Metastases | No | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Accepted |
| 593 | Breast cancer | Yes | No | Yes | Yes | EQ-5D | Literature/TAG | Accepted | Accepted |
| 595 | Lung cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Not accepted | Not accepted |
| 598 | Ovarian cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 600 | Lung cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 604 | Blood and BM cancers | No | Yes | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 611 | Ovarian cancer | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 612 | Breast cancer | Yes | Yes | No | No | EQ-5D | Literature/TAG | Not accepted | Not accepted |
| 619 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 627 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 628 | Lung cancer | No | No | Yes | No | Mapping | Literature/TAG | Accepted | Not accepted |
| 630 | Sarcoma | Yes | No | Yes | Yes | EQ-5D | EQ-5D | Not accepted | Not accepted |
| 632 | Breast cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 638 | Lung cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 639 | Breast cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 641 | Blood and BM cancers | Yes | Yes | Yes | No | EQ-5D | Literature/TAG | Not accepted | Not accepted |
| 642 | Blood and BM cancers | Yes | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 643 | Lung cancer | Yes | No | Yes | No | EQ-5D | Literature/TAG | Accepted | Accepted |
| 644 | Sarcoma | Yes | No | Yes | No | EQ-5D | Literature/TAG | Not accepted | Accepted |
| 645 | Renal cancer | No | Yes | No | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 649 | Blood and BM cancers | No | No | No | No | Literature/TAG | Literature/TAG | Not accepted | Not accepted |
| 650 | Renal cancer | Yes | Yes | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 658 | Bladder cancer | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Accepted |
| 660 | Prostate cancer | Yes | Yes | Yes | Yes | EQ-5D | Literature/TAG | Accepted | Accepted |
| 661 | Head and neck cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Accepted | Not accepted |
| 663 | Blood and BM cancers | Yes | No | Yes | Yes | Literature/TAG | Literature/TAG | Accepted | Accepted |
| 666 | Liver cancers | Yes | No | Yes | No | EQ-5D | EQ-5D | Not accepted | Not accepted |

BM: bone marrow; EORTC QLQ: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; EQ-5D: EuroQol 5 Dimensions; FACT: Functional Assessment of Cancer Therapy; HRQOL: health-related quality-of-life; TA: technology appraisal; TAC: technology appraisal committee; TAG: technology appraisal guidance.